SHELSpar Asparagine Depletion Therapy

Asparagine depletion against leukemias and lymphomas

• 150,000 diagnosis per year in the U.S.
• Treatment failures and limited applicability of asparagine depletion are due to:
– Immune reactions (to non-human origin enzyme and/or to PEG)
– Silent inactivation
– Pancreatitis, hepatotoxicity, coagulopathy, CNS complications, etc.


• Asparaginase encapsulated within SHELS
• Shielded enzyme prevents immune reactions, avoids silent inactivation
• PEG-free formulation avoids reactions to PEG
• IV or IM administration for long term systemic depletion

Leave a Reply

Your email address will not be published. Required fields are marked *